MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions…
An institutional-grade, numbers-driven thesis on MLTX — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 16, 2026, TradersQuant's model rates MoonLake Immunotherapeutics (MLTX) 51/100 with a 12-month base-case forecast of $42.50 — +158.0% versus the current price of $16.47. MoonLake Immunotherapeutics trades at $16.47 in the Healthcare sector, with a market capitalisation of $1.39B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for MLTX is $42.50, implying +158.0% versus the current price. The model's 12-month scenario range runs from $5.62 (bear) to $11.80 (bull), with a base case of $8.24.
On the fundamentals, MoonLake Immunotherapeutics shows a P/E of -4.3, trailing revenue of $0, revenue growth of +0.0% YoY. This page also tracks MLTX's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
MLTX currently carries a TradersQuant composite score of 51/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $42.50 implies +158.0% from $16.47. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for MLTX is $42.50, about +158.0% versus the latest price of $16.47. Consensus is based on 19 analysts.
TradersQuant's 12-month model forecast for MLTX is a base case of $8.24, ranging from $5.62 (bear) to $11.80 (bull), an expected return of -50.0%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for MLTX over the next 12 months is $8.24 in the base case (bear $5.62, bull $11.80), versus today's price of $16.47. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for MLTX — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates MLTX's fair value at $42.50, implying +158.0% of expected upside versus the current price.
MoonLake Immunotherapeutics does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
